Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT

Abstract TP53 gene alteration confers inferior prognosis in refractory/relapse aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). From September 2016 to September 2020, 257 r/r B-NHL patients were assessed for eligibility for two trials in our center, assessing anti-CD19 and anti-CD22 chimeric anti...

Full description

Bibliographic Details
Main Authors: Jia Wei, Min Xiao, Zekai Mao, Na Wang, Yang Cao, Yi Xiao, Fankai Meng, Weimin Sun, Ying Wang, Xingcheng Yang, Liting Chen, Yicheng Zhang, Haichuan Zhu, Shangkun Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang
Format: Article
Language:English
Published: Nature Publishing Group 2022-04-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-022-00924-0

Similar Items

Similar Items